繊維症:メカニズムから医薬品へ
Neil C Henderson1,2, Florian Rieder3,4, Thomas A Wynn5
1University of Edinburgh Centre for Inflammation Research, The Queen's Medical Research Institute, Edinburgh BioQuarter, Edinburgh, UK.
Nature
|November 26, 2020
まとめ
死因の主要な原因である 線維症は ダイナミックなプロセスで 回復不能ではありません 重要なメカニズムを標的として 線維性疾患を治療するための新しい治療戦略を 研究中です
科学分野:
- 病理生物学
- 翻訳医学
- 再生医療
背景:
- 繊維症はどの臓器にも影響し 工業国における死亡の45%に寄与します
- 以前は進行的で不可逆的と考えられていた 線維症は今やダイナミックなプロセスとして理解されています
- 抗線維菌標的の特定と効果的なヒト治療法の開発の間に大きなギャップがあります.
研究 の 目的:
- 繊維症のメカニズムを解剖するための実験的戦略について議論する.
- 線維症治療の翻訳的なアプローチを探求する.
- 繊維性疾患に対する 精密医療の出現を強調する
主な方法:
- 様々な臓器系における臨床前モデルと臨床試験のレビュー
- 繊維症を調節する細胞および分子機構の分析.
- 治療開発のためのトランスレーション戦略の検討
主要な成果:
- 繊維症はダイナミックで 潜在的に逆戻り可能なプロセスで 過去の仮定に異議を唱えます
- 実験的な戦略により 細胞および分子の繊維症の 重要な調節因子を明らかにしています
- 翻訳的なアプローチは 繊維症の治療における 精密医療の道を開いています
結論:
- 繊維症は 治療の可能性のある ダイナミックなプロセスです
- 繊維症の病理生物学を理解することは 新しい治療法の開発に不可欠です
- 精密医療は 繊維性疾患の管理に 素晴らしい未来をもたらします
さらに関連する動画
関連する概念動画
Cystic Fibrosis: Management
318
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
318
Introduction to Fibroblasts
3.6K
Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
3.6K
Ultrasound II: Endoscopic Ultrasound and FibroScan
332
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
332
Inflammatory Bowel Disease IV: Pharmacological Management
311
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
311
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
318
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
318
Drugs for Treatment of Constipation-Predominant IBS
524
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
524


